Brief: Cue Biopharma Presents Positive Data Update From Ongoing Phase 1 Trials Of Cue-101 For Recurrent/Metastatic Hpv+ Head And Neck Squamous Cell Carcinoma At The 2023 American Society Of Clinical Oncology Annual Meeting
25/05/2023 23:10
May 25 (Reuters) - Cue Biopharma Inc CUE.O :
* CUE BIOPHARMA PRESENTS POSITIVE DATA UPDATE FROM ONGOING
PHASE 1
TRIALS OF CUE-101 FOR RECURRENT/METASTATIC HPV+ HEAD AND NECK
SQUAMOUS CELL CARCINOMA AT THE 2023 AMERICAN SOCIETY OF CLINICAL
ONCOLOGY (ASCO) ANNUAL MEETING
* CUE BIOPHARMA - 100% OF PATIENTS TREATED WITH CUE-101+
PEMBROLIZUMAB AT RECOMMENDED PHASE 2 DOSE REMAIN ALIVE TO DATE
FOLLOWING TREATMENT IN STUDY
Source text for Eikon: ID:nGNX1g1CMx
Further company coverage: CUE.O
((Reuters.Briefs@thomsonreuters.com;))